Protocol Ledger

NCT07807007 · Phase II · COMPLETED

Efficacy and Safety of CP006 Inhalation Powder in Participants With Asthma

Interventional Phase II clinical trial protocol NCT07807007 sponsored by Shanghai Xin Huanghe Pharmaceutical Co in Respiratory and Pulmonary, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-11-21 Enrollment: 150 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT07807007
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)150 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07807007
Protocol FieldVerified Registry Value
NCT IdentifierNCT07807007
Consolidated Lead SponsorShanghai Xin Huanghe Pharmaceutical Co
Therapeutic Condition CohortRespiratory and Pulmonary
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment150 participants (ACTUAL)
Registered Start Date2025-11-21
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07807007
Hospital Research SiteLocationSite Profile
Peking University People's HospitalBeijing, ChinaOpen Hospital Dossier ->
The First Hospital of Hebei Medical UniversityShijiazhuang, ChinaOpen Hospital Dossier ->
The Second Affiliated Hospital of Soochow UniversitySuzhou, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI